Stonebridge Financial Group LLC Invests $170,000 in Zoetis Inc. (NYSE:ZTS)

Stonebridge Financial Group LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,041 shares of the company’s stock, valued at approximately $170,000.

Several other hedge funds have also bought and sold shares of ZTS. Cherry Creek Investment Advisors Inc. boosted its position in Zoetis by 2.0% during the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares during the period. Hancock Whitney Corp lifted its stake in shares of Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after buying an additional 61 shares during the last quarter. Strategy Asset Managers LLC boosted its holdings in shares of Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after buying an additional 62 shares during the period. Procyon Advisors LLC grew its stake in Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after buying an additional 63 shares during the last quarter. Finally, Aberdeen Wealth Management LLC raised its holdings in Zoetis by 1.9% in the 3rd quarter. Aberdeen Wealth Management LLC now owns 3,566 shares of the company’s stock valued at $697,000 after acquiring an additional 68 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZTS. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Piper Sandler decreased their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $214.00.

Zoetis Stock Performance

Shares of Zoetis stock opened at $173.99 on Thursday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company has a market cap of $78.50 billion, a PE ratio of 32.70, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The company has a 50 day moving average of $169.11 and a 200-day moving average of $179.11. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 37.59%.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.